Elutia Inc. (ELUT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report covers the period ended September 30, 2025. Elutia Inc. is a commercial-stage biotechnology company focused on biologics and local drug delivery. The reporting period is defined by a major strategic shift: the sale of the Company's Cardiac Implantable Electronic Device (CIED) Business to Boston Scientific and Cardiac Pacemakers, Inc. on October 1, 2025. Consequently, the CIED segment is reported as Discontinued Operations. The Company now operates two continuing segments: Women's Health and Cardiovascular.
Key Financial Metrics (Continuing Operations)
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $3.32M | $3.66M | $9.02M | $11.65M |
| Gross Profit | $1.85M | $1.79M | $4.68M | $5.39M |
| Gross Margin | 55.8% | 48.9% | 51.9% | 46.3% |
| Operating Loss | $(5.21M) | $(9.18M) | $(20.35M) | $(23.25M) |
| Net Loss (Continuing Ops) | $(0.38M) | $3.34M (Income) | $(9.36M) | $(38.19M) |
| Net Loss (Total) | $(3.87M) | $1.29M (Income) | $(17.41M) | $(44.89M) |
| Cash & Equivalents | $4.72M | $13.24M (Dec 2024) | N/A | N/A |
| Total Debt (Long-Term) | $21.10M | $22.60M (Dec 2024) | N/A | N/A |
Note: Total Net Loss includes a loss of $3.49M from Discontinued Operations for Q3 2025.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9.3% in Q3 2025 and 22.6% in the nine months ended Sept 30, 2025, compared to prior year periods. This was driven by a decline in Women's Health sales (SimpliDerm) following the termination of the distribution agreement with Tiger Aesthetics Medical in October 2025.
- Margin Expansion: Gross margin improved to 55.8% in Q3 2025 from 48.9% in Q3 2024. This improvement is attributed to the termination of the exclusive distribution agreement with LeMaitre Vascular in April 2025, allowing the Company to resume direct sales of Cardiovascular products at higher end-user pricing.
- Reduced Litigation Costs: Litigation costs, net, decreased significantly to $0.85M in Q3 2025 from $4.68M in Q3 2024, as nearly all FiberCel cases have been settled.
- Warrant Liability Gain: The Company recognized a non-cash gain of $5.10M in Q3 2025 (and $12.52M for the nine months) due to the revaluation of warrant liabilities, which significantly reduced the reported net loss from continuing operations.
- Debt Repayment: While the balance sheet as of Sept 30, 2025, shows $26.1M in SWK debt, the Company fully repaid this facility on October 1, 2025, using proceeds from the CIED Business sale.
Guidance, Outlook, and Risks
- Strategic Pivot: The Company is pivoting to focus on its proprietary drug-eluting biomatrix (DEB) platform, specifically the development of NXT-41 and NXT-41x for breast reconstruction and soft tissue repair.
- Liquidity: As of September 30, 2025, cash was $4.72M. Following the October 1, 2025, CIED sale and debt repayment, the Company reported approximately $44M in cash as of October 31, 2025. Management believes this is sufficient to fund operations for at least one year.
- Nasdaq Compliance: On November 7, 2025, the Company received notice from Nasdaq that its stock price had been below the $1.00 minimum bid price for 30 consecutive days. The Company has a 180-day compliance period (until May 6, 2026) to regain compliance, potentially via a reverse stock split.
- Legal Contingencies:
- FiberCel Litigation: 44 active cases remain. The Company has accrued $12.7M for probable losses. Insurance coverage for these costs is exhausted.
- VBM Litigation: 13 active cases remain. The Company has accrued $3.7M. Insurance coverage remains available for these costs.
- Medtronic Litigation: Ongoing dispute regarding indemnification obligations; no loss is currently considered probable or estimable.
Investor Verification Checklist
- CIED Sale Proceeds: Verify the final net cash proceeds from the CIED sale to Boston Scientific/CPI after the $27.8M debt repayment and transaction costs.
- Nasdaq Compliance Plan: Monitor the Company's progress in regaining the $1.00 minimum bid price or the execution of a reverse stock split before May 2026.
- Women's Health Distribution: Assess the impact of the terminated Tiger Aesthetics agreement on future SimpliDerm sales and the success of new direct sales strategies.
- Litigation Exposure: Review updates on the 44 unsettled FiberCel cases, as the Company has no remaining insurance coverage for these liabilities.
- R&D Milestones: Track the development timeline and regulatory status of NXT-41 and NXT-41x, which are critical to the Company's future growth strategy.